#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glomerulonephritis minimal lesion Anal cancer Neoplasm Malignant fibrous histiocytoma Anti-neutrophil cytoplasmic antibody positive vasculitis Fibrosarcoma Thromboangiitis obliterans Scedosporium infection Emphysema Skin angiosarcoma Rhabdomyosarcoma recurrent Cortical dysplasia Factor IX deficiency Skin cancer Progressive multifocal leukoencephalopathy More trials…

    Learn about Rare Diseases

    Wiskott-Aldrich syndrome – Basic Information Waldenstrom’s macroglobulinaemia – Treatment Cholangitis sclerosing – Basic Information Osteosarcoma Synovial sarcoma metastatic – Trials in Disease Bronchopulmonary dysplasia – Life with Disease Methylmalonic acidaemia – Diagnostics Alveolar rhabdomyosarcoma – Trials in Disease Fabry’s disease – Diagnostics Angelman’s syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bleomycin Sulfate Vosoritide Lapatinib Cenegermin SPY002 Cdr132L Io103 Acetate XMAB942 Xevinapant Lenvatinib NORETHISTERONE ACETATE INSULIN DEGLUDEC Plitidepsin Dextrose Bp AMODIAQUINE Satoreotide Tetraxetan Sulfamethoxazole Benfotiamine Mavacamten For-6219 More therapies…

    Learn about Your Condition

    Primary hyperoxaluria Chorea Progressive multiple sclerosis Implantation complication Syphilis Osteonecrosis of jaw Biliary cancer metastatic Sjogren's syndrome Keratosis follicular Palpitations Stomatitis Juvenile absence epilepsy Piriformis syndrome Phaeochromocytoma Small fibre neuropathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma refractory

  • Dose optimization study of ibrutinib drug combination in adult patients with haematological diseases

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Waldenstrom’s macroglobulinaemia
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Talquetamab
    • Linvoseltamab
    • Teclistamab
    Denmark

  • Phase II Study of Teclistamab Plus Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma After 1–3 Prior Therapies

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Teclistamab
    • Pomalidomide
    Denmark Estonia Finland Norway

  • Cemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    France Italy Poland Spain

  • AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    • Plasma cell myeloma
    Investigated Drugs:
    • AZD0120
    • Bortezomib
    • Carfilzomib
    France Germany Italy Norway Poland Spain

  • A study of Cesnicabtagene autoleucel compared to a drug combination for patients with relapsed or refractory multiple myeloma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • AUTOLOGOUS GENETICALLY MODIFIED T LYMPHOCYTES TRANSDUCED WITH LENTIVIRUS EXPRESSING CAR PROTEIN DIRECTED AGAINST BCMA
    • Bortezomib
    • Carfilzomib
    The Netherlands

  • A study of the safety and effectiveness of REGN17372 and linvoseltamab in adults with relapsed or refractory multiple myeloma

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Diphenhydramine Hydrochloride
    • Linvoseltamab
    • Dexamethasone
    Greece
Previous Page
1 2 3 4 5 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!